Sharpe ratio for CS2 skin investors: how to know if your portfolio actually beat the market
Most skin traders track P&L. Almost none track risk-adjusted return. The result: people who took insane volatility feel like winners when they merely got lucky, and disciplined investors who avoided dumb drawdowns look like underperformers. This post explains the framework that fixes that, with concrete data from 6 years of CS2 skin index history.
The 30-second definition
Sharpe ratio is a single number that tells you how much return you got for the risk you took. The formula is:
Sharpe = (R_portfolio - R_risk_free) / σ_portfolio
where:
R_portfolio = annualized return of the asset/portfolio
R_risk_free = annualized return of a "do-nothing" benchmark
σ_portfolio = annualized standard deviation of returnsHigher is better. A Sharpe of 1.0 means you got 1 unit of excess return per unit of volatility — considered good. 0.5 is decent. Negative Sharpe means you took risk and ended below the risk-free rate — your time would have been better spent doing nothing.
The metric was introduced by William Sharpe in 1966 (Nobel Prize 1990) and remains the most cited risk-adjusted return metric in finance — used by every institutional asset manager from Bridgewater to Renaissance.
Why this matters specifically for skin portfolios
The CS2 skin market has volatility somewhere between public equities and crypto. STI 500 (broad market index) ran annualized volatility of ~25% over 2020-2026 — close to small-cap equities. Individual blue-chip skins (AK-47 Asiimov, M4A4 Howl, AWP Asiimov) have annualized volatility of 35-50% — comparable to large-cap crypto. Event-driven skins (Souvenir AWP Dragon Lore, sticker capsules from Major tournaments) can hit 80%+.
With volatility that high, raw return numbers are deceiving:
- A skin that returned +200% over 5 years sounds incredible — until you realize it had a -70% drawdown along the way and 90% annualized vol.
- Another skin returning +60% with 20% vol is far better risk-adjusted, even though the raw number looks worse.
- Without Sharpe, you can't tell if your portfolio outperformed because you were skilled, took crazy risk that happened to pay off, or just got lucky during a bull cycle.
Sharpe ratios across the STI family (2020-2026)
Live Sharpe data for the seven STI indices, computed against Brazilian CDI as the in-window risk-free rate (~10% annualized over the window). Methodology details at /en/methodology.
| Index | Total return | Annual vol | Sharpe |
|---|---|---|---|
| STI Cases | +788.9% | ~32% | +0.65 |
| STI 1000 | +75.3% | ~26% | +0.04 |
| STI 500 | +65.1% | ~25% | −0.07 |
| STI 30 | +37.5% | ~30% | −0.24 |
| STI 100 | +29.7% | ~26% | −0.32 |
| STI Stickers | +28.6% | ~38% | −0.18 |
| STI Agents | −0.8% | ~40% | −0.27 |
The headline finding: most STI tiers have negative Sharpe vs Brazilian CDI. STI Cases is the standout positive — driven by structural scarcity (drop retired) plus post-CS2 launch demand surge — and is the only tier where the risk-adjusted picture is unambiguously good.
For an investor in BRL, the period 2020-2026 was one where Selic averaged ~10%/year — exceptionally high by global standards. The same Sharpe calculation against US Treasury 4-month bills (~3-4% over the window) gives meaningfully better numbers for the skin tiers. The choice of risk-free benchmark matters enormously, and Skin Trackers uses CDI in-window because the platform anchors in BRL even though prices are in USD.
Cross-asset comparison: where do skins sit?
| Asset (2020-2026) | CAGR | Vol | Sharpe |
|---|---|---|---|
| Bitcoin | ~50% | ~60% | +0.65 |
| S&P 500 (USD) | ~17% | ~18% | +0.40 |
| CDI (BRL benchmark) | ~10% | ~0% | 0 (baseline) |
| STI 500 (broad CS2 market) | +8.8% | ~25% | −0.07 |
Methodological caveat: Bitcoin and S&P 500 Sharpes above use the same in-window CDI as risk-free rate, for cross-comparability with STI tiers. Strictly, USD-denominated assets should be measured against US Treasury bills as risk-free — that's the orthodox convention. The numbers stay directionally similar, but the BTC and S&P Sharpes would shift up by ~0.1-0.2 with the orthodox treatment. The point of cross-asset comparison here is to rank assets, not to quote absolute Sharpes for each.
What makes a "good" Sharpe for an alt asset?
- Sharpe < 0: investor took risk and got paid less than risk-free. Bad in absolute terms; sometimes acceptable for insurance-type holdings or long-term inflation hedges.
- Sharpe 0 to 0.3: marginal. Probably not worth the effort vs passive index. This is where most STI tiers landed in 2020-2026.
- Sharpe 0.3 to 0.6: solid. Comparable to S&P 500 long-term. Reasonable allocation decision.
- Sharpe 0.6 to 1.0: very good. Bitcoin, hedge fund target zone, top-decile single stocks. STI Cases sits here.
- Sharpe > 1.0: exceptional. Either extraordinary skill, structural luck baked in (unlikely to persist), or sample bias.
How to compute the Sharpe ratio of your own portfolio
Three steps:
- Compute monthly returns. Mark-to-market your portfolio at end of each month (current Steam Market value of each skin × quantity, summed). Compute
return_t = value_t / value_(t-1) - 1for each month. - Annualize. Mean monthly return × 12 = annualized return. Standard deviation of monthly returns × √12 = annualized volatility.
- Subtract risk-free, divide by vol. Take annualized return, subtract ~10% (CDI) or ~4% (US Treasury 4mo) depending on your benchmark, divide by annualized vol. That's your portfolio Sharpe.
For Skin Trackers users: monthly portfolio value is computed automatically via /inventario if you've imported via Steam login. Compare against STI benchmark Sharpe at /indices. If your portfolio Sharpe is higher than STI 30, you generated alpha. If it's lower, you took risk you weren't paid for — consider rebalancing.
Limitations: what Sharpe doesn't capture
- Fat tails. Sharpe assumes normally distributed returns. Skin returns have fat tails (sticker capsules from old Majors can spike +500% in a month after a cultural moment). Sharpe penalizes that as "volatility," but for collectors, those are the signal, not the noise.
- Liquidity. Two assets with identical Sharpe but different liquidity are not equivalent. Vending an AWP Dragon Lore takes weeks; vending an SPY ETF share takes seconds. Sharpe is silent on this.
- Fees. Steam Market fee of 15% + Brazilian capital gains tax of 15% can flip a positive-Sharpe asset to negative on realized returns. The STI Sharpes above are gross — net of fees, the picture worsens.
- Drawdown sequencing. A portfolio with -50% drawdown followed by +100% recovery has the same Sharpe as one with steady +25% — but the lived experience is wildly different. Calmar ratio (return ÷ max drawdown) captures this; Sortino partially does. Use both alongside Sharpe.
Frequently asked
What is Sharpe ratio in plain English?
Sharpe ratio is a single number that tells you how much return you got for the risk you took. The formula is (your return − risk-free rate) ÷ volatility. Higher is better. A Sharpe of 1.0 means your asset returned 1 percentage point above risk-free per unit of standard deviation — generally considered good. Negative Sharpe means you took risk and ended up below risk-free assets — generally considered bad. The concept was introduced by William Sharpe in 1966 (Nobel Prize 1990) and remains the most cited risk-adjusted return metric in finance.
Why does Sharpe ratio matter specifically for skin investors?
Skin returns are deceiving on raw P&L. A skin that returned +200% over 5 years sounds incredible — but if it had a -70% drawdown along the way and 90% annualized volatility, the risk-adjusted picture is much worse than a boring index that returned +60% with 25% volatility. Without Sharpe, you can't tell if you outperformed because you were skilled, took crazy risk that happened to pay off, or got lucky. The CS2 skin market has volatility somewhere between equities and crypto — Sharpe lets you compare your portfolio against the proper benchmark.
What's a 'good' Sharpe ratio for an alternative asset like skins?
Reference points: S&P 500 long-term Sharpe is about 0.4-0.5. Bitcoin since 2013 has Sharpe around 0.6-0.8 depending on window. Hedge funds aim for 1.0+ as institutional standard. The STI 30 (broad CS2 skin index) has Sharpe around -0.24 over 2020-2026 — meaning skin investors didn't get paid for the risk they took, in absolute terms vs Brazilian CDI. STI Cases is the exception with positive Sharpe (~+0.6) due to outsized returns. Anything above 0.5 in alt assets is genuinely good; above 1.0 is exceptional and probably has structural luck baked in.
How do I compute the Sharpe ratio of my own skin portfolio?
Three steps. First, compute monthly returns of your portfolio (mark-to-market value at end of each month, divided by prior month, minus 1). Second, annualize the mean return (multiply by 12) and the standard deviation (multiply by √12). Third, subtract the risk-free annual rate (~10% for Brazilian CDI in 2020-2026, or ~4-5% for US Treasury in 2024-26 in USD terms) and divide by the annualized standard deviation. Skin Trackers exposes all the inputs needed — monthly portfolio value via /inventario, STI index series via /api/indices for benchmark comparison.
What's the difference between Sharpe and Sortino ratio?
Sharpe penalizes both upside and downside volatility equally — its denominator is total standard deviation. Sortino only penalizes downside volatility (returns below a threshold, usually risk-free). For investors who think 'big upside swings are great, big downside swings are bad,' Sortino captures the asymmetry better. For CS2 skins specifically, where upside spikes (event-driven price runs) are common, Sortino tends to be 1.5-2x higher than Sharpe for the same asset. Use Sharpe to compare against equities (where it's the convention); use Sortino when you specifically want to reward 'good vol' over 'bad vol'.
Why is the risk-free rate so important in Sharpe calculations?
The risk-free rate is what you could earn doing nothing risky. If a skin returns 12% per year with 30% volatility, but Brazilian CDI is paying 13% risk-free, your Sharpe is negative — you took risk for less than free money. This is why STI Sharpe ratios look bad in 2020-2026: Selic averaged ~10%/year over the window. Compare the same returns against US Treasury 4-month bills (typical institutional risk-free for USD assets) and the Sharpe improves substantially. Skin Trackers uses CDI as the in-window risk-free rate for Sharpe calculations because the platform anchors in BRL even though prices are in USD — methodology note documented at /metodologia.
Can I just use raw returns instead of Sharpe?
You can, but you'll fool yourself. Raw return tells you 'how much money I made'. Sharpe tells you 'how much money I made per unit of suffering'. Two skins with identical raw returns can have wildly different Sharpe ratios — and the high-Sharpe one is the one to copy, because the low-Sharpe one was just lucky. Professional asset managers don't lead with raw returns in their pitch decks; they lead with Sharpe (or its cousins: Sortino, Calmar, Information Ratio). For retail skin investors, even imperfect Sharpe estimation beats no risk-adjustment at all.
What are the limitations of Sharpe ratio for CS2 skins?
Three main caveats. First, Sharpe assumes normally distributed returns — skins have fat tails (event-driven price spikes from Major tournaments, Operation drops). Second, Sharpe doesn't account for liquidity — vending an AWP Dragon Lore takes weeks; vending an SPY ETF share takes seconds. Two assets with identical Sharpe but different liquidity are NOT equivalent. Third, fees aren't typically baked in — Steam Market 15% fee + 15% Brazilian capital gains can flip a positive-Sharpe asset to negative on realized returns. Skin Trackers' methodology page documents all three; cross-reference Calmar (drawdown-adjusted) and net-of-fees calculations for fuller picture.
Where to go from here
- Compare your portfolio against the STI 30 benchmark at /indices/sti-30.
- Read the cross-asset 6-year backtest at /en/blog/skins-vs-cdi-vs-bitcoin-2020-2026 — Sharpe is one piece; total return context is another.
- For full methodology including how Sharpe, Sortino, Calmar, and VaR are computed in our pipeline, see /en/methodology.
- All raw STI snapshots are public via /api/indices — reproduce these Sharpe numbers in your own notebook, ideally with your own risk-free rate convention.
Not financial advice. Skin Trackers is editorial — we publish analysis, not recommendations. Decide for yourself based on your horizon, risk tolerance, and tax situation.